Waksigrip

Roman name

Vaxigrip #

The composition and the form of

one dose of vaccine contains purified inactivated influenza virus three strains (of which the Na-antigen change according to the annual WHO and the European Committee), mercury (less than or equal to 0.05 mg), formaldehyde (less than or equal to 0.10 mg), traces neomitina, buffered solution (from sodium chloride, potassium chloride, sodium hydrogen dwuvodnyi, digidrofosfata potassium and water for injection). Solution for injection in the injection of one dose (0.25 and 0.5 ml) or in vials to 5 ml.

Characteristics

A vaccine for the prevention of influenza. Purified inactivated trehvalentnaya split-wakcina made from splits of inactivated influenza viruses, of which removed reactogenne lipids. Influenza viruses are cultured chicken embryos and inaguiruyutza formalin. The composition of the vaccine changes every year in accordance with the epidemic situation, and contains three strains of influenza virus antigennaya structure equivalent to the strains recommended by WHO.

Of drugs

A vaccine for the prevention of influenza. If vaccination rates waksigrip from 80-95% of people vaccinated inducyruetsa (stimulated) of the specific gumoralland and woven immunity (the defence organism against H5N1 influenza). Antiviral antibodies developed in 10-15 days after vaccination and stored for at least 1 year.

Farmakodinamika

The immunization in 80-95% of patients, a specific humoral and cellular immunity. Antiviral antibodies in a protective epidemiologist reached in 10-15 days after vaccination and stored for at least 1 year. High efficiency vaccine is the presence of both surface and internal antigens.

Indications

Prevention of influenza, particularly in the elderly (over 65 years), patients with respiratory illnesses and cardiovascular systems, sickle cell disease, congenital and acquired immunodeficiency; From persons as a result of his or her work with a new range of social contacts (medical personnel, teachers, etc.).

Pregnancy and lactation

The refrain from vaccination in the first quarter of pregnancy, although there is no evidence of a possible risk to the foetus and human fertility using Waksigripa. Whether vaccination during this period to be assessed in relation to the risk of influenza infection.

Contraindications

Гиперчувствительност ь (including yeast to chicken eggs to neomitino), a children's age (up to 6 months).

Side-Effects

Local reaction, pain, tightness, redness at the injection. The general reaction (in the first 48 h), increased body temperature, headache, cough.

Patient interaction

There is no evidence of incompatibility with other drugs. Because interest is the combination with a vaccine for the prevention of disease caused by pnevmokokkami because those with a risk of complications from influenza forward are also at risk of complications from pneumococcal infections.

Precautions

For the vaccination of patients with immunodeficiency to the doctor consulted.

Dosing and Administration

V / m or m / c (before use vesboltati to homogenization). The following vaccination scheme : 1) children aged 6 months to 35 months - 0.25 ml; 2) children from the ages of 3 years to 8 years - 0.5 ml; 3) adults and children of 9 years and older - 0.5 Ml.detam than nine years for the first time wakcinirutmsa against influenza shows a two doses at intervals of at least one month.

Storage conditions

r-r d / in. : The temperature 2-8 ° C (not freezing)

Shelf life

r-r d / in. : 1 year

Indications for use

Prevention of influenza, especially among people with the highest risk of complications (the elderly, children and people with chronic diseases), as well as with the people as a result of his or her work with a new range of social contacts (medical personnel, teachers, etc.).

Form of

Splitawakktina injection in the 0.5 ml. Each dose contains inactivated (inactive) purified influenza virus strains of the three (three species such as A, B, C), the composition of which the Na-antigen change every year in accordance with the recommendations of the WHO (World Health Organization) and the European Committee. This combination yields a specific immuninet (vulnerability) to a certain type of flu.

Directory → Immunotropona funds → Vaccines, serums, fagi → Waksigrip